Tandem Diabetes Care (TNDM) Stock Price, News & Analysis

+0.37 (+0.79%)
(As of 05/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.12 million shs
Average Volume
1.74 million shs
Market Capitalization
$3.06 billion
P/E Ratio
Dividend Yield
Price Target

Tandem Diabetes Care MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
7.4% Downside
$43.80 Price Target
Short Interest
12.42% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
1.14mentions of Tandem Diabetes Care in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.70) to ($1.10) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.47 out of 5 stars

Medical Sector

318th out of 922 stocks

Surgical & Medical Instruments Industry

41st out of 96 stocks

TNDM stock logo

About Tandem Diabetes Care Stock (NASDAQ:TNDM)

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

TNDM Stock Price History

TNDM Stock News Headlines

Tandem Diabetes Care (NASDAQ:TNDM) PT Raised to $55.00
Q1 2024 Tandem Diabetes Care Inc Earnings Call
Tandem Diabetes Care Inc
Should You Invest in Tandem Diabetes Care (TNDM)?
See More Headlines
Receive TNDM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
10 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$747.72 million
Book Value
$3.76 per share


Free Float
Market Cap
$3.06 billion

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

TNDM Stock Analysis - Frequently Asked Questions

Should I buy or sell Tandem Diabetes Care stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TNDM shares.
View TNDM analyst ratings
or view top-rated stocks.

What is Tandem Diabetes Care's stock price target for 2024?

10 brokerages have issued 12-month target prices for Tandem Diabetes Care's shares. Their TNDM share price targets range from $34.00 to $55.00. On average, they anticipate the company's share price to reach $43.80 in the next twelve months. This suggests that the stock has a possible downside of 7.4%.
View analysts price targets for TNDM
or view top-rated stocks among Wall Street analysts.

How have TNDM shares performed in 2024?

Tandem Diabetes Care's stock was trading at $29.58 at the beginning of 2024. Since then, TNDM stock has increased by 59.9% and is now trading at $47.30.
View the best growth stocks for 2024 here

When is Tandem Diabetes Care's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our TNDM earnings forecast

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) released its earnings results on Wednesday, February, 21st. The medical device company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.04. The medical device company had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative trailing twelve-month return on equity of 34.38% and a negative net margin of 18.37%.

When did Tandem Diabetes Care's stock split?

Tandem Diabetes Care shares reverse split before market open on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What guidance has Tandem Diabetes Care issued on next quarter's earnings?

Tandem Diabetes Care updated its second quarter 2024 earnings guidance on Friday, May, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $205.0 million-$205.0 million, compared to the consensus revenue estimate of $205.0 million.

What is John Sheridan's approval rating as Tandem Diabetes Care's CEO?

11 employees have rated Tandem Diabetes Care Chief Executive Officer John Sheridan on John Sheridan has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Block (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

Who are Tandem Diabetes Care's major shareholders?

Tandem Diabetes Care's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.92%), Capital World Investors (5.67%), Jennison Associates LLC (3.96%), Janus Henderson Group PLC (3.41%), Bellevue Group AG (3.15%) and Champlain Investment Partners LLC (2.34%). Insiders that own company stock include Brian B Hansen, Christopher J Twomey, Christopher J Twomey, David B Berger, Dick Allen, Elizabeth Anne Gasser, James Leal, John F Sheridan, Kathleen Mcgroddy-Goetz, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson, Rebecca B Robertson, Shannon Marie Hansen and Susan Morrison.
View institutional ownership trends

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TNDM) was last updated on 5/18/2024 by Staff

From Our Partners